A5067182682- CAR-T cell therapy research
- Viral Infectious Diseases and Gene Expression in Insects
- Integrated Circuits and Semiconductor Failure Analysis
- Biosimilars and Bioanalytical Methods
- Virus-based gene therapy research
- Lymphoma Diagnosis and Treatment
- Immune Cell Function and Interaction
- Advancements in Semiconductor Devices and Circuit Design
- Hematopoietic Stem Cell Transplantation
- Immunotherapy and Immune Responses
- Neutropenia and Cancer Infections
- Cancer Immunotherapy and Biomarkers
- Antifungal resistance and susceptibility
- Silicon Carbide Semiconductor Technologies
- Clostridium difficile and Clostridium perfringens research
- Nanowire Synthesis and Applications
- Fungal Infections and Studies
- CNS Lymphoma Diagnosis and Treatment
- Monoclonal and Polyclonal Antibodies Research
- SARS-CoV-2 and COVID-19 Research
- Chronic Lymphocytic Leukemia Research
- T-cell and B-cell Immunology
- Sepsis Diagnosis and Treatment
- Biomedical Ethics and Regulation
- Gut microbiota and health
Ludwig-Maximilians-Universität München
2019-2025
LMU Klinikum
2019-2025
Harvard University
2024-2025
Massachusetts General Hospital
2024-2025
Broad Institute
2025
Massachusetts Institute of Technology
2025
German Cancer Research Center
2021-2024
Deutschen Konsortium für Translationale Krebsforschung
2021-2024
Cancer Research Center
2024
Heidelberg University
2021-2023
<h3>Background</h3> CD19-directed chimeric antigen receptor T-cell therapy (CAR-T) represents a promising treatment modality for an increasing number of B-cell malignancies. However, prolonged cytopenias and infections substantially contribute to the toxicity burden CAR-T. The recently developed CAR-HEMATOTOX (HT) score—composed five pre-lymphodepletion variables (eg, absolute neutrophil count, platelet hemoglobin, C-reactive protein, ferritin)—enables risk stratification hematological...
Approximately 30%-40% of patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) infused CD19-targeted chimeric antigen receptor (CAR) T cells achieve durable responses. Consensus guidelines suggest avoiding bendamustine before apheresis, but specific data in this setting are lacking. We report distinct outcomes after CAR T-cell therapy according to previous exposure.
CD19 CAR T-cells represent a practice-changing treatment modality for advanced B-cell malignancies. However, refractory cytopenias have emerged as potentially life-threatening complication that can persist long after lymphodepleting chemotherapy. Whether stem cell rescue is feasible and efficacious CAR-T has not been addressed. In this retrospective multi-center study, we describe clinical characteristics outcomes of 13 patients with hyporegenerative bone marrow (BM) failure CAR-T, which...
Prolonged cytopenias after chimeric antigen receptor (CAR) T cell therapy are a significant clinical problem and the underlying pathophysiology remains poorly understood. Here, we investigated how expansion dynamics serum proteomics affect neutrophil recovery phenotypes CD19-directed CAR therapy. Survival favored patients with "intermittent" (e.g., recurrent dips) compared to either "quick" or "aplastic" recovery. While intermittent displayed increased expansion, aplastic exhibited an...
Despite revolutionary efficacy of CD19-CAR-T cell therapy (CAR-T) in aggressive B lymphoma, many patients still relapse mostly early. In early failure, distinct drugs support CAR-T which makes reliable and prediction imminent relapse/refractoriness critical. A complete metabolic remission (CR) on Fluor-18-Deoxyglucose (FDG) Positron-Emission-Computed Tomography (PET) 30 days after (PET30) strongly predicts progression-free survival (PFS), but fails a relevant proportion patients. We aimed to...
Abstract Background Prolonged myelosuppression following CD19-directed CAR T-cell transfusion represents an important, yet underreported, adverse event. The resulting neutropenia and multifactorial immunosuppression can facilitate severe infectious complications. Case presentation We describe the clinical course of a 59-year-old patient with relapsed/refractory DLBCL who received Axicabtagene-Ciloleucel (Axi-cel). developed ASTCT grade I CRS IV ICANS, necessitating admission to neurological...
Secondary CNS involvement in systemic B-cell lymphoma (SCNSL) is difficult to treat and displays dismal clinical outcomes. Chimeric antigen receptor (CAR) T cells emerged as a powerful treatment for lymphoma. We aimed evaluate whether CAR also represent safe effective therapy SCNSL.We retrospectively searched our institutional database patients with SCNSL treated CD19-directed cells.We identified 10 cases, including 7 intraparenchymal lesions 3 leptomeningeal disease. staging at 1 month...
Although CD19-directed chimeric antigen receptor T-cell therapy (CD19.CAR-T) has proven clinical efficacy for multiple refractory B-cell malignancies, over 50% of patients ultimately relapse. Recent evidence underlined the critical role host in determining treatment responses. In this retrospective observational study 106 with relapsed/refractory large lymphoma receiving standard-of-care CD19.CAR-T, we analyzed impact immunometabolic features and detailed body composition measurements on...
Early fever after chimeric antigen receptor T-cell (CAR-T) therapy can reflect both an infection or cytokine release syndrome (CRS). Identifying early infections in the setting of CRS and neutropenia represents unresolved clinical challenge. In this retrospective observational analysis, events (day 0-30) were characterized as versus 62 patients treated with standard-of-care CD19.CAR-T for relapsed/refractory B-cell non-Hodgkin lymphoma. Routine serum inflammatory markers (C-reactive protein...
The advent of chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment landscape refractory B-cell malignancies. Real-world evidence highlighted high incidence hematological toxicity, including prolonged and profound cytopenia. Here, we present a case bone marrow (BM) failure in 57-year old man with DLBCL-type Richter transformation receiving tisagenlecleucel standard-of-care setting. His clinical course was notable for underlying BM infiltration, severe cytokine...
Abstract Antitumor therapy with CD19-targeted chimeric antigen receptor (CAR) modified T cells is highly efficient. However, treatment often complicated by a unique profile of unpredictable neurotoxic adverse effects varying degrees known as immune effector cell–associated neurotoxicity syndrome (ICANS). We examined 96 patients receiving CAR for refractory B-cell malignancies at 2 major T-cell centers to determine whether serum levels neurofilament light chain (NfL), marker neuroaxonal...
Chimeric antigen receptor T-cell (CAR-T) therapy is associated with a distinct toxicity profile that includes cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity (ICANS). CRS characterized by the of pro-inflammatory cytokines such as interleukin 6 (IL-6) closely linked to CAR-T expansion bystander cells like monocytes/macrophages. In other hyperinflammatory states, obesity contributes inflammatory cascades acts risk factor for disease severity. We aimed study...
Ziel/Aim: Chimeric antigen receptor (CAR) T-cell therapy has proven highly effective in relapsed and refractory large B-cell lymphomas. Yet, it remains an open question how to identify potential non-responders ahead of treatment further improve their outcome. Several international research groups are currently working on the integration metabolic tumor volume (MTV), measured by 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography (PET), into newly developed models. Therefore, we...
Immunocompromised patients are exposed to a heightened risk of invasive fungal infections (IFIs) such as aspergillosis and mucormycosis causing substantial morbidity mortality.1,2 Surgical debridement along with systemic antifungal drugs is the current treatment strategy,2 but prognosis these still very poor.1,2 Therefore, new therapeutic approaches urgently needed. Recently published in vitro vivo studies imply benefit checkpoint inhibition for salvage IFI.3-7 Here, we report first...
Real-world evidence suggests a trend toward inferior survival of patients receiving CD19 chimeric antigen receptor (CAR) T-cell therapy in Europe (EU) and with tisagenlecleucel. The underlying logistic, patient- disease-related reasons for these discrepancies remain poorly understood. In this multicenter retrospective observational study, we studied the patient-individual journey from CAR-T indication to infusion, baseline features, outcomes 374 treated tisagenlecleucel (tisa-cel) or...
Abstract Immune deficits after CD19 chimeric antigen receptor (CAR) T‐cell therapy can be long‐lasting, predisposing patients to infections and non‐relapse mortality. In B‐cell non‐Hodgkin lymphoma (B‐NHL), the prognostic impact of immune reconstitution (IR) remains ill‐defined, detailed cross‐product comparisons have not been performed date. this retrospective observational study, we longitudinally characterized lymphocyte subsets immunoglobulin levels in 105 B‐NHL assess patterns recovery...
Treatment of hematological malignancies with chimeric antigen receptor modified T cells (CART) is highly efficient, but often limited by an immune effector cell-associated neurotoxicity syndrome (ICANS). As conventional MRI unremarkable during ICANS, we aimed to examine whether resting-state functional (rsfMRI) suitable depict and quantify brain network alterations underlying ICANS in the individual patient.The dysconnectivity index (DCI) based on rsfMRI was longitudinally assessed systemic...